Table 7 Prescription of the type of chemotherapy based on pathological stage and biology
Stage | CMF-like | Anthracyclines | Anthracyclines + Taxanes | Taxanes |
|---|---|---|---|---|
Luminal A | ||||
IA* | 3 (25.0%) | 8 (66.7%) | 0 (0%) | 1 (8.3%) |
IB** | 16 (27.1%) | 36 (61.0%) | 7 (11.9%) | 0 (0%) |
II*** | 16 (7.5%) | 113 (53.1%) | 75 (35.2%) | 9 (4.2%) |
III**** | 5 (7.4%) | 12 (17.6%) | 47 (69.1%) | 4 (5.9%) |
Total | 40 (11.4%) | 169 (48.0%) | 129 (36.6%) | 14 (4.0%) |
Luminal B | ||||
A* | 1 (10.0%) | 9 (66.7%) | 0 (0%) | 0 (0%) |
IB** | 7 (15.9%) | 31 (61.0%) | 7 (11.4%) | 1 (2.3%) |
II*** | 10 (7.7%) | 67 (53.1%) | 44 (33.8%) | 9 (6.9%) |
III**** | 0 (0%) | 9 (17.6%) | 36 (78.3%) | 1 (2.2%) |
Total | 18 (7.8%) | 116 (50.4%) | 85 (37.0%) | 11 (4.8%) |
HER2 | ||||
IA* | 0 (0%) | 22 (88.0%) | 2 (8.0%) | 1 (4.0%) |
IB** | 4 (5.2%) | 54 (70.1%) | 18 (23.4%) | 1 (1.3%) |
II*** | 4 (3.3%) | 55 (45.1%) | 61 (50.0%) | 2 (1.6%) |
III**** | 3 (6.7%) | 6 (13.3%) | 36 (80.0%) | 0 (0%) |
Total | 11 (4.1%) | 137 (50.9%) | 117 (43.5%) | 4 (1.5%) |
Triple negative | ||||
IA* | 4 (23.5%) | 8 (47.1%) | 4 (23.5%) | 1 (5.9%) |
IB** | 8 (14.3%) | 30 (53.6%) | 14 (25.0%) | 4 (7.1%) |
II*** | 3 (4.0%) | 38 (50.7%) | 32 (42.7%) | 2 (2.7%) |
III**** | 2 (15.4%) | 0 (0%) | 9 (69.2%) | 2 (15.4%) |
Total | 17 (10.6%) | 76 (47.2%) | 59 (36.6%) | 9 (5.6%) |